A Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Briquilimab in Participants With Allergic Asthma
A Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Briquilimab in Participants With Allergic Asthma
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Jasper
- Email: clinicaltrials@jaspertx.com
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 1N4
- University Of Calgary
-
Edmonton, Alberta, Canada, T6G 2R3
- University of Alberta
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6T 1Z4
- University of British Columbia
-
-
Ontario
-
Hamilton, Ontario, Canada, L8N 3Z5
- McMaster University
-
-
Quebec
-
Québec, Quebec, Canada, G1V 0A6
- University of Laval
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Canada, S7N 5A2
- University of Saskatchewan
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Men and women 18 to 65 years of age; stable, allergic asthma; history of episodic wheeze and shortness of breath; forced expiratory volume in 1 second (FEV1) at baseline at least 70% of the predicted value; able to comprehend and follow all required study procedures; willing and able to sign an informed consent form; positive methacholine challenge at baseline (concentration of methacholine causing 20% decrease in FEV1 [PC20] PC20 ≤ 16 mg/mL or PD20 equivalent to ≤400µg); and positive skin-prick test and positive allergen-induced early and late airway bronchoconstriction to common aeroallergens.
Exclusion Criteria:
- Worsening of asthma or respiratory infection in the preceding 6 weeks; lung disease other than allergic asthma; prior treatment with a c-Kit inhibiting therapy; anaphylaxis to any parenterally administered biologics; use of asthma medications (note: intermittent doses of short-acting β2-agonist are allowed once weekly for relief of symptoms but prophylactic use for exercise is allowed as-needed); pregnant or lactating women; and women actively seeking pregnancy or who are not using adequate contraception.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
|
Subcutaneous Administration
|
|
Experimental: Briquilimab
|
Subcutaneous Administration
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
To evaluate the safety and tolerability of briquilimab in mild-to-moderate asthmatic participants
Time Frame: From signing the informed consent form (ICF) through end of trial (EOT) visit (up to 4.5 months)
|
Incidence and/or severity of AEs, treatmentemergent adverse events (TEAEs), SAEs, AEIs, and AEs leading to discontinuation. Incidence of clinically significant abnormal laboratory values and vital signs. |
From signing the informed consent form (ICF) through end of trial (EOT) visit (up to 4.5 months)
|
|
To compare the effect of treatment with briquilimab vs placebo on the allergen-induced LAR
Time Frame: 3-7 hours after allergen challenge between Briquilimab and Placebo at week 6
|
Allergen-induced LAR will be measured by maximum percentage fall in FEV1 during the period 3-7 hours after the allergen challenge and compared between briquilimab and placebo at week 6.
|
3-7 hours after allergen challenge between Briquilimab and Placebo at week 6
|
|
To compare the effect of treatment with briquilimab vs placebo on the allergen-induced LAR
Time Frame: 3-7 hours after allergen challenge between Briquilimab and Placebo at week 6
|
Allergen-induced LAR will be measured by area under the FEV1 time-response curve [AUC] during the period 3-7 hours after the allergen challenge and compared between briquilimab and placebo at week 6.
|
3-7 hours after allergen challenge between Briquilimab and Placebo at week 6
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
To compare of the allergen-induced early asthmatic response (EAR) between briquilimab and placebo.
Time Frame: 0-2 hours after the allergen challenge and compared briquilimab and placebo at week 6
|
Allergen-induced EAR will be measured by maximum percentage fall in FEV1 during the period 0-2 hours after the allergen challenge and compared briquilimab and placebo at week 6.
|
0-2 hours after the allergen challenge and compared briquilimab and placebo at week 6
|
|
To compare of the allergen-induced early asthmatic response (EAR) between briquilimab and placebo.
Time Frame: 0-2 hours after the allergen challenge and compared briquilimab and placebo at week 6
|
Allergen-induced EAR will be measured by area under the FEV1 time-response curve [AUC] during the period 0-2 hours after the allergen challenge and compared briquilimab and placebo at week 6.
|
0-2 hours after the allergen challenge and compared briquilimab and placebo at week 6
|
|
Comparison of allergen-induced inflammatory mediators at 7h and 24h post allergen, between briquilimab and placebo
Time Frame: 7 hours and 24 hours after the allergen challenge, compared between briquilimab and placebo at week 6.
|
Changes from pre-allergen challenge sputum inflammatory mediators to 7 hours and 24 hours after the allergen challenge, compared between briquilimab and placebo at week 6.
|
7 hours and 24 hours after the allergen challenge, compared between briquilimab and placebo at week 6.
|
|
Comparison of the allergen-induced shift in AHR to methacholine at 24 hours after the allergen challenge, between briquilimab and placebo.
Time Frame: 24 hours after the allergen challenge compared between briquilimab and placebo at week 6.
|
Changes from pre-allergen challenge AHR to 24 hours after the allergen challenge assessed by methacholine PD20, and compared between briquilimab and placebo at week 6.
|
24 hours after the allergen challenge compared between briquilimab and placebo at week 6.
|
|
Comparison of the allergen-induced changes in sputum leukocytes at 7h and 24h post allergen challenge, between the briquilimab and placebo.
Time Frame: 7 hours and 24 hours after the allergen challenge, compared between briquilimab at week 6. and placebo.
|
Changes from pre-allergen challenge sputum leukocytes to 7 hours and 24 hours after the allergen challenge, compared between briquilimab and placebo at week 6.
|
7 hours and 24 hours after the allergen challenge, compared between briquilimab at week 6. and placebo.
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Medical Director, Jasper Therapeutics
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Disease Attributes
- Pathological Conditions, Signs and Symptoms
- Lung Diseases
- Lung Diseases, Obstructive
- Asthma
- Hypersensitivity
- Respiratory Tract Diseases
- Immune System Diseases
- Chronic Disease
- Bronchial Diseases
- Respiratory Hypersensitivity
- Hypersensitivity, Immediate
- Substandard Drugs
- Pharmaceutical Preparations
- Counterfeit Drugs
Other Study ID Numbers
Other Study ID Numbers
- JSP-CP-012
- 2024-516164-28-00 (Ctis)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.